NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome
Myelodysplastic Syndrome/Acute Myeloid Leukemia

Interventions: Drug: Azacitidine
Drug: Cytarabine
Other: Laboratory Biomarker Analysis
Drug: Decitabine
Biological: Nivolumab
Drug: Midostaurin

First Posted Date: 2017-03-28

Last Posted Date: 2025-01-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 78

Registration Number: NCT03092674

Locations: 🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
🇺🇸
Anchorage Oncology Centre, Anchorage, Alaska, United States

and more 502 locations

Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology

Phase 2

Completed

Conditions: Esophagogastric Junction
Gastric Cancer
Gastric Adenocarcinoma

Interventions: Procedure: Surgery
Drug: Cisplatin
Drug: Mitomycin C
Drug: Sodium Thiosulfate
Procedure: Tumor Biopsy
Diagnostic Test: CT C/A/P
Diagnostic Test: PET-CT
Diagnostic Test: MRI
Diagnostic Test: EKG

First Posted Date: 2017-03-28

Last Posted Date: 2025-02-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT03092518

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

Phase 2

Recruiting

Conditions: Thymoma
Thymic Carcinoma

Interventions: Drug: Avelumab

First Posted Date: 2017-03-10

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT03076554

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Discovery and Validation of Plasma DNA Methylation Biomarker for Detection of Stomach Cancer

Completed

Conditions: Stomach Cancer
Gastric Cancer

First Posted Date: 2017-03-10

Last Posted Date: 2020-02-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 440

Registration Number: NCT03076567

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer

Phase 2

Completed

Conditions: Medullary Thyroid Cancer (MTC)

Interventions: Drug: Pembrolizumab

First Posted Date: 2017-03-07

Last Posted Date: 2021-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT03072160

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Long-Term Stability of Oral Microbiome Samples

Completed

Conditions: Oral Microbiota
Long Term Sample Stability

First Posted Date: 2017-03-03

Last Posted Date: 2020-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT03068546

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

Phase 2

Completed

Conditions: Metastatic Myxoid Liposarcoma
Metastatic Synovial Sarcoma
Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7
Recurrent Mycosis Fungoides and Sezary Syndrome
Refractory Mycosis Fungoides and Sezary Syndrome
Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7
Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7
Unresectable Synovial Sarcoma

Interventions: Biological: Interferon Gamma-1b
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab

First Posted Date: 2017-02-24

Last Posted Date: 2023-10-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT03063632

Locations: 🇺🇸
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 4 locations

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

Phase 3

Active, not recruiting

Conditions: Metastatic Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v7
Sarcomatoid Renal Cell Carcinoma
Stage II Renal Cell Cancer AJCC v7
Unclassified Renal Cell Carcinoma

Interventions: Procedure: Nephrectomy
Other: Patient Observation
Biological: Nivolumab
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2017-02-16

Last Posted Date: 2025-04-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 819

Registration Number: NCT03055013

Locations: 🇺🇸
Straub Clinic and Hospital, Honolulu, Hawaii, United States
🇺🇸
Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States
🇺🇸
McFarland Clinic - Boone, Boone, Iowa, United States

and more 411 locations

Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004

Phase 2

Terminated

Conditions: Colorectal Tumors
Colorectal Neoplasms
Colorectal Cancer
Colorectal Carcinoma
Colorectal Adenocarcinoma

Interventions: Drug: Bevacizumab
Drug: Avelumab
Drug: 5-Fluorouracil (FU)
Biological: Ad-CEA vaccine
Drug: Leucovorin
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2017-02-13

Last Posted Date: 2021-12-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT03050814

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists

Phase 1

Recruiting

Conditions: Polycystic Ovary Syndrome

Interventions: Drug: Mirabegron
Other: B Complex Plus Vitamin C Tablets

First Posted Date: 2017-02-10

Last Posted Date: 2025-06-05

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 100

Registration Number: NCT03049462

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Home Terms & Conditions Privacy Policy